0.1040EUR-2.99%Mkt Cap: —P/E: —1d ago
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company deve…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value36.07M $
Revenue (TTM)708.70K $
Gross Profit708.70K $
Net Income (TTM)-13.08M $
Revenue/Share0.0043 USD
Last Price0.1040 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees13
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINFR0013183985
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.02
EV/Revenue50.90
P/S—
P/B-0.91
EPS (TTM)-0.63
EPS (Forward)—
52W Range
0.098527% of range0.1190
52W High0.1190 EUR
52W Low0.0985 EUR
Profitability
Gross Margin100.00%
Oper. Margin-705.96%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA-72.68%
Growth
Revenue Growth-32.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.97M $
CapEx (TTM)—
FCF Margin-1110.64%
FCF Yield—
Net Debt11.36M $
Net Debt/EBITDA-0.95
Balance Sheet
Debt/Equity—
Current Ratio0.39
Quick Ratio0.32
Book Value/Sh-0.1130 EUR
Cash/Share0.0110 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.24.38M
Float168.52M
Insiders7.07%
Institutions41.19%
Technical
SMA 500.4375 (-76.2%)
SMA 2000.5936 (-82.5%)
Beta0.64
S&P 52W Chg20.80%
Avg Vol (30d)68.65K
Avg Vol (10d)5.13K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—